ReviewCurrent drug targets2014
The role of P2Y₁₂ receptor and activated platelets during inflammation.
Review in Current drug targets, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 57 citations in OpenAlex.
- Trial
- Review
- Role and recent progress of P2Y12 receptor in cancer development.Purinergic signalling · 2025Review
- MAVS signaling shapes microglia responses to neurotropic virus infection.Journal of neuroinflammation · 2024Article
- Platelet P2YBritish journal of pharmacology · 2024Review
- Platelets and platelet-derived vesicles as an innovative cellular and subcellular platform for managing multiple sclerosis.Molecular biology reports · 2023Review
- A role for platelets in metabolic reprogramming of tumor-associated macrophages.Frontiers in physiology · 2023Review
- Diagnostic and therapeutic value of P2Y12R in epilepsy.Frontiers in pharmacology · 2023Review
- Platelet-lymphocyte co-culture serves as an ex vivo platform of dynamic heterotypic cross-talk.Journal of cell communication and signaling · 2022Article
- Variations in the Gene Expression Profile in Atherosclerotic Patients with Non-Fatal ACS: A Preliminary Study.International journal of molecular sciences · 2022Article
- Physical Aggression and Coronary Artery Calcification: A North Texas Healthy Heart Study.International journal of behavioral medicine · 2022Article
- Primary Percutaneous Coronary Intervention with High-Bolus Dose Tirofiban: The FASTER (Favorite Approach to Safe and Effective Treatment for Early Reperfusion) Multicenter Registry.Journal of interventional cardiology · 2022Article
- The Role of Purinergic Signaling in Heart Transplantation.Frontiers in immunology · 2022Review
- Pleiotropic Effects of Ticagrelor: Influence onDrug design, development and therapy · 2022Article
- Sex-related differences in the response of anti-platelet drug therapies targeting purinergic signaling pathways in sepsis.Frontiers in immunology · 2022Article
- Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.Immunopharmacology and immunotoxicology · 2021Review
- Opposite Modulatory Effects of Crataegus aronia Aqueous Extract on Platelet Aggregation in Rats.Chinese journal of integrative medicine · 2021Article
- Cangrelor ameliorates CLP-induced pulmonary injury in sepsis by inhibiting GPR17.European journal of medical research · 2021Article
- Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets.Physiological reviews · 2021Review
- Microglia and Neuroinflammation: What Place for P2RY12?International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Platelets play an important role not only during thrombosis, but also in modulating immune responses through their interaction with immune cells and by releasing inflammatory mediators upon activation. The P2Y12 receptor is a Gi-coupled receptor that not only regulates ADP-induced aggregation but can also dramatically potentiate secretion, when platelets are activated by other stimuli. Considering the importance of P2Y12 receptor in platelet function, a class of antiplatelet drugs, thienopyridines, have been designed and successfully used to prevent thrombosis. This review will focus on the role of activated platelets in inflammation and the effects that P2Y12 antagonism exerts on the inflammatory process. A change in platelet functions was noted in patients treated with thienopyridines during inflammatory conditions, suggesting that platelets may modulate the inflammatory response. Further experiments in a variety of animal models of diseases, such as sepsis, rheumatoid arthritis, myocardial infarction, pancreatitis and pulmonary inflammation have also demonstrated that activated platelets influence the inflammatory state. Platelets can secrete inflammatory modulators in a P2Y12-dependent manner, and, as a result, directly alter the inflammatory response. P2Y12 receptor may also be expressed in other cells of the immune system, indicating that thienopyridines could directly influence the immune system rather than only through platelets. Overall the results obtained to date strongly support the notion that activated platelets significantly contribute to the inflammatory process and that antagonizing P2Y12 receptor can influence the immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.